Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fadraciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fadraciclib overview

Fadraciclib is under development for the treatment of hematological malignancies including relapsed or refractory acute myeloid leukemia, biliary tract cancer, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), myelodysplastic syndrome, relapsed and refractory chronic lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma (CTCL and PTCL) and solid tumors including laryngeal cancer, endometrial cancer, neuroblastoma, ovarian, pancreatic cancer, lung cancer, metastatic breast cancer, hormone receptor positive breast cancer, triple negative and HER2 negative breast cancer, hepatocellular carcinoma, colorectal cancer (including KRAS mutant), lymphomas and uterine cancers. It is a small molecule administered orally and intravenously. CYC065 is a potent derivative of seliciclib. It is a cell cycle kinase inhibitor (CDK 2 and CDK9). CYC065 targets the CDK/cyclin complexes.  It was also under development for the treatment of inflammation in COVID-19, acute lymphocytic leukemia, diffuse large b-cell lymphoma, multiple myeloma patients.

Cyclacel Pharmaceuticals overview

Cyclacel Pharmaceuticals (Cyclacel) is a biopharmaceutical company primarily engaged in the development of innovative therapies. These therapies target various phases of cell cycle control for the treatment of cancer and other serious diseases. The company’s major products in development include fadraciclib, a dual inhibitor of cyclin dependent kinases (CDK), and CYC140, a polo-like kinase 1 inhibitor. The company collaborates with renowned cancer research organizations such as MD Anderson Cancer Center and Dana Farber Cancer Institute to enhance its clinical programs. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.

For a complete picture of Fadraciclib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.